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Abstract
The present study was undertaken to examine multifaceted therapeutic effects of vascular endothelial growth factor (VEGF)
in a rat spinal cord injury (SCI) model, focusing on its capability to stimulate proliferation of endogenous glial progenitor
cells. Neural stem cells (NSCs) can be genetically modified to efficiently transfer therapeutic genes to diseased CNS. We
adopted an ex vivo approach using immortalized human NSC line (F3 cells) to achieve stable and robust expression of VEGF
in the injured spinal cord. Transplantation of NSCs retrovirally transduced to overexpress VEGF (F3.VEGF cells) at 7 days after
contusive SCI markedly elevated the amount of VEGF in the injured spinal cord tissue compared to injection of PBS or F3
cells without VEGF. Concomitantly, phosphorylation of VEGF receptor flk-1 increased in F3.VEGF group. Stereological
counting of BrdU+ cells revealed that transplantation of F3.VEGF significantly enhanced cellular proliferation at 2 weeks
after SCI. The number of proliferating NG2+ glial progenitor cells (NG2+/BrdU+) was also increased by F3.VEGF. Furthermore,
transplantation of F3.VEGF increased the number of early proliferating cells that differentiated into mature
oligodendrocytes, but not astrocytes, at 6 weeks after SCI. F3.VEGF treatment also increased the density of blood vessels
in the injured spinal cord and enhanced tissue sparing. These anatomical results were accompanied by improved BBB
locomotor scores. The multifaceted effects of VEGF on endogenous gliogenesis, angiogenesis, and tissue sparing could be
utilized to improve functional outcomes following SCI.
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Introduction
Spinal cord injury (SCI) results in severe and permanent
disability, yet there is no single effective therapeutic option to
improve functional outcomes. Growth factor treatment is consid-
ered as one of the important components for the future
combinatorial strategies to repair injured spinal cord [1,2]. Vascular
endothelial growth factor (VEGF) was originally characterized as a
potent stimulator of angiogenesis. Later, multifaceted trophic effects
of VEGF have been uncovered in nervous tissue [3]. VEGF
provides direct protective effects on neurons [4,5] and enhances
neurite outgrowth [6]. It also supports survival and proliferation of
various glial cells [7,8]. The neuroprotective effects of VEGF as well
as the angiogenic activity led to improved functional outcomes in
animal models of traumatic spinal cord injury and other
neurological disorders [9–11].
Endogenous stem or progenitor cells that can differentiate into
neurons and glial cells are also present in adult spinal cord [12]. The
progenitors in glial lineage are stimulated to proliferate in response
to SCI [13–16]. Proliferating glial progenitors are persistently found
until several weeks after injury [13], and they are believed to
differentiate into mature glial cells, eventually replacing the lost
oligodendrocytes and astrocytes [16]. These findings suggest a
promising possibility that mobilization of endogenous glial progen-
itors can provide a therapeutic opportunity to repair the white
matter damaged by traumatic SCI. Recently, the versatile actions of
VEGF has been expanded to stimulating proliferation of endoge-
nous neural stem or progenitor cells, and VEGF was shown to
increase endogenous neurogenesis after stroke [11,17]. However,
potential effects of VEGF on the glial progenitor cells in the spinal
cord after injury have not been investigated.
The present study was undertaken to examine multifaceted
therapeutic effects of VEGF in a rat model of contusive SCI,
focusing on its capability to stimulate proliferation of endogenous
glial progenitor cells. Sustained delivery of growth factors to
diseased CNS remains a demanding challenge. Engraftment of
genetically modified neural stem cells (NSCs) has proved to be an
excellent approach to provide various growth factors [18–21]. For
stable and robust expression of VEGF, we transplanted VEGF
overexpressing immortalized neural stem cells (NSCs) into the
injured spinal cord. Our data showed that transplantation of
VEGF overexpressing NSCs stimulated proliferation of glial
progenitor cells and increased the number of newly born
oligodendrocytes. We also report that the ex vivo delivery of VEGF
enhanced angiogenesis and tissue sparing, leading to improved
locomotor recovery.
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Results
Ex vivo VEGF delivery to the injured spinal cord using
immortalized human NSCs
One of the immortalized human NSC line (F3) was retrovirally
transduced with human VEGF cDNA to generate VEGF
overexpressing NSC line (F3.VEGF). At 1 week after SCI,
parental F3 NSCs or VEGF overexpressing NSCs (F3.VEGF)
were transplanted at 2 mm rostral and caudal to the epicenter.
Grafted NSCs were detected by immunoreactivity against human
specific mitochondria at 1 week after transplantation (Fig. 1A–C).
The number of surviving F3.VEGF cells was higher than that of
F3 cells. The percentage of surviving cells versus total transplanted
cells was 15.964.3 and 28.767.6% for F3 and F3.VEGF groups,
respectively (N= 5 for each group). The majority of surviving cells
were observed at the lesion epicenter, suggesting that grafted cells
migrated towards the injury sites. Fewer cells were found to be
scattered in distant areas rostral and caudal to the lesion. Most of
the grafted NSCs did not incorporate proliferation marker BrdU
(Fig. 1D), indicating that they no longer proliferate after being
transplanted into the injured spinal cord. Grafted cells were still
detected at 5 week post-transplantation, but the number of
surviving cells (both F3 and F3.VEGF cells) was markedly reduced
by that time point; 9.163.3 (F3) and 11.664.8% (F3.VEGF) of
transplanted cells were detected (N= 5 for each group).
The amount of VEGF in the injured spinal cord tissue was
determined by ELISA assay. Transplantation of F3.VEGF cells
dramatically upregulated the level of VEGF at 2 weeks after SCI (7
days after transplantation) (2.7060.724 ng/ml, 3.2560.78 ng/ml,
and 16.4062.05 ng/ml for PBS, F3, and F3.VEGF groups,
respectively; N=5 for each group) (Fig. 1E). Concomitantly,
immunoblot analysis revealed that F3.VEGF grafts increased
phosphorylation of VEGF receptor flk-1 (Fig. 1F). In contrast, the
expression of flk-1 protein itself was not affected by the ex vivoVEGF
delivery. The amount of VEGF was still higher in F3.VEGF group
until 6 weeks than in PBS or F3 group, but the extent of increase
sharply declined compared to that measured at 2 weeks after SCI
(2.4560.89 ng/ml, 2.9960.81 ng/ml, and 4.7761.07 ng/ml for
PBS, F3, and F3.VEGF groups, respectively).
Proliferation of glial progenitor cells by F3.VEGF grafts
To determine the effects of ex vivo delivery of VEGF on cellular
proliferation after SCI, rats received BrdU for three consecutive
days before being sacrificed at 2 weeks after SCI (1 week after
transplantation). Stereological counting of BrdU+ cells showed that
transplantation of VEGF overexpressing NSCs increased the
number of proliferating cells compared to the other groups
(Fig. 2A–C): Animals with F3.VEGF grafts contained more than
1.5 fold higher number of BrdU+ cells than those with control PBS
injection or parental F3 grafts at 2 weeks (p,0.001 compared to
PBS or F3 group) (Fig. 2D). The effect of F3.VEGF on cellular
proliferation was significant across the rostrocaudal regions (Fig. 2E).
The cellular proliferation was most active at the epicenter region in
all groups, and there was no remarkable difference between the
regions 1.8 mm rostral and caudal to the epicenter. We next
determined the effects of VEGF on the proliferation of NG2+ glial
progenitor cells. About 40% of BrdU+ cells were doubly positive to
NG2 across the different experimental groups (Fig. 3A–C). The
number of NG2+/BrdU+ cells per 1 mm3 of spared tissue was
greatly increased by F3.VEGF grafts at 2 weeks compared to PBS or
F3 injected group (Fig. 3D) (p,0.001 compared to PBS or F3
groups). The rostrocaudal distribution of proliferating NG2+ glial
progenitor cells was very similar to that of BrdU+ cells (Fig. 3E). The
increase of NG2+/BrdU+ cells by F3.VEGF was most obvious at
the epicenter region, and there was no remarkable difference
between the regions 1.8 mm rostral and caudal to the epicenter.
Long-term fate of early proliferating glial progenitor cells
To determine long-term fate of early proliferating glial progenitor
cells, BrdU injected animals were allowed to survive 4 more weeks
and then the phenotypic differentiation of BrdU+ cells was
examined at 6 weeks after SCI. We found that approximately
30% (34.961.2%, 29.860.9%, and 32.261.0% for PBS, F3, and
F3.VEGF groups, respectively) of early proliferating cells (BrdU+)
differentiated into CC1+ mature oligodendrocytes (Fig. 4A). Some
of BrdU+ cells were colocalized with GFAP (Fig. 4B), but their
percentage (14.061.4%, 14.361.0%, and 11.560.7% for PBS, F3,
and F3.VEGF groups, respectively) was less than that of CC1+/
BrdU+ cells. Stereological assessment showed that the number of
newly born oligodendrocytes was significantly increased by
transplantation of F3.VEGF (p,0.05 compared to PBS or F3
group) (Fig. 4C). In contrast, the number of newly born GFAP+
astrocytes was not different between the groups (Fig. 4D). Double
labeling for BrdU and the neuron-specific markers (NeuN or
MAP2) showed no colocalization (data not shown), indicating that
early proliferating cells did not differentiate into neurons regardless
of experimental interventions.
F3.VEGF grafts enhance angiogenesis, tissue sparing, and
functional recovery
We determined the extent of angiogenesis by measuring the
density of vWF positive microvessels. As seen in Fig. 5, F3.VEGF
grafts dramatically (by more than 5-fold compared to PBS group)
increased the density of vWF+ vessels in the injured spinal cord,
indicating that the extent of angiogenesis was greatly enhanced by
the ex vivo delivery of VEGF. This angiogenesis-promoting effect
by F3.VEGF was evident across the rostrocaudal extent (Fig. 5D).
The highest vessel density was observed at the caudal region.
SCI usually leaves large central cavities around the epicenter
region with varying amount of remaining gray matter and a
peripheral rim of spared white matter. Animals with F3.VEGF
grafts showed smaller cavitary lesions and a larger amount of
spared tissue (Fig. 6A–I). Quantification data showed that
transplantation of F3.VEGF significantly increased the volume
of spared spinal cord tissue (p,0.001 compared to PBS or F3
group) (Fig. 6J). At the same time, the volume of spared white
matter was also increased in F3.VEGF group (p,0.001 compared
to PBS or F3 group) (Fig. 6K). This tissue sparing effect was also
observed by transplantation of F3 cells. The volume of cystic
cavities was reduced by F3.VEGF at 6 weeks after SCI (p,0.001
compared to PBS or F3 group, respectively) (Fig. 6L).
Locomotor recovery was evaluated using BBB score. The
hindlimbs of all the animals in the three groups were completely
paralyzed one day after contusion injury, and locomotor function
gradually improved thereafter. At 4 weeks after injury (3 weeks after
transplantation), the mean score of rats with F3.VEGF grafts was
significantly higher than those for the other groups, and remained
higher thereafter (Fig. 7). Repeated measures two-way ANOVA
revealed a significant treatment effect on locomotor recovery
(p,0.001), and one-way ANOVA at each time point showed
significant differences between F.VEGF and the other two groups at
4, 5, and 6 weeks after SCI.
Discussion
The present experiment adopted an ex vivo approach for stable
and robust expression of VEGF in the injured spinal cord. As
expected, transplantation of VEGF overexpressing NSCs elevated
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the level of VEGF in the injured spinal cord until 6 weeks after
SCI. Furthermore, phosphorylation of the VEGF receptor flk-1,
which plays a major role in proliferation of precursor cells,
angiogenesis, and neuroprotection [3,17,22], was markedly
enhanced by F3.VEGF grafts. These findings indicate that the ex
vivo approach using immortalized NSCs ensured a stable and
effective increase of the ambient concentration of VEGF in the
injured spinal cord, which would be highly demanding or very
costly to achieve by direct infusion of VEGF [23]. As gene delivery
vehicles, NSCs exhibit inherent long-distance migratory capabil-
ities and a remarkable capacity to integrate with host neural tissue
[21]. Especially, immortalized human NSCs have shown excep-
Figure 1. Ex vivo delivery of VEGF carried by human neural stem cells (NSCs) to the injured spinal cord. (A–C) Detection of transplanted
NSCs by human specific mitochondria (hMito) staining at 1 week after transplantation (2 weeks after injury). Surviving F3 (B) and F3.VEGF (C) cells
were observed around the lesion cavities. Control PBS group did not show any immunoreactivity to hMito (A). (D) Most of the transplanted NSCs did
not incorporate BrdU. An arrow indicates a transplanted NSC colocalized with BrdU. Asterisks indicate lesion cavities at the epicenter. Scale bars;
100 um. (E) Levels of VEGF production in spinal cord tissue were measured by ELISA at 2 and 6 weeks after injury (1 and 5 weeks after
transplantation). White, hatched, and black bars represent PBS (N= 5), F3 (N= 5), and F3.VEGF (N= 5) groups, respectively. * p,0.05, *** p,0.001 by
one-way ANOVA followed by Tukey’s posthoc analysis. (F) Western blot analysis of VEGF receptor flk-1 and phosphorylated flk-1 (p-flk-1).
doi:10.1371/journal.pone.0004987.g001
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Figure 2. Transplantation of F3.VEGF enhanced cellular proliferation. (A–C) Representative images of BrdU stained sections from PBS (A), F3
(B), and F3.VEGF (C) groups. Scale bars; 50 um. (D) The number of BrdU+ cells per 1 mm3 of spinal cord tissue was stereologically counted and
compared between the three groups at 2 weeks after injury. (E) The number of BrdU+ cells was separately counted at the epicenter (designated as E)
and 1.8 mm rostral and caudal (designated as R and C, respectively) to the epicenter. * p,0.05, ** p,0.01, *** p,0.001 by one-way ANOVA followed
by Tukey’s posthoc analysis. White, hatched, and black bars represent PBS (N= 8), F3 (N= 8), and F3.VEGF (N= 8) groups, respectively.
doi:10.1371/journal.pone.0004987.g002
Figure 3. Proliferation of NG2+ glial progenitor cells. (A–C) Representative images of spinal cord sections doubly stained with BrdU (dark
brown) and NG2 (dark blue) cells from PBS (A), F3 (B), and F3.VEGF (C) groups. Arrows indicate NG2+/BrdU+ cells and arrow heads NG2 single positive
cells. Scale bars; 50 um. (D) The number of NG2+/BrdU+ cells per 1 mm3 of spinal cord tissue was stereologically counted and compared between the
three groups at 2 weeks after injury. (E) The number of NG2+/BrdU+ cells was separately counted at the epicenter (designated as E) and 1.8 mm
rostral and caudal (designated as R and C, respectively) to the epicenter. * p,0.05, ** p,0.01, *** p,0.001 by one-way ANOVA followed by Tukey’s
posthoc analysis. White, hatched, and black bars represent PBS (N= 5), F3 (N= 5), and F3.VEGF (N= 5) groups, respectively.
doi:10.1371/journal.pone.0004987.g003
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tional capability to find pathological regions [24]. The majority of
F3.VEGF NSCs in this study were also found around the lesion
cavities, even though they were injected at 2 mm rostral and
caudal to the epicenter. Thus, it is highly likely that F3.VEGF
grafts functioned as localized and sustained cellular sources
providing VEGF directly to the lesion site.
The major finding of this study was that F3.VEGF grafts
markedly increased the number of BrdU+ proliferating cells.
Approximately 40% of all the proliferating cells were NG2+ cells
in all the groups. This percentage is comparable to the data of the
previous report that almost half of the acutely dividing cells were
NG2 immunoreactive [14]. Other proliferating cells after SCI are
thought to encompass macrophages/microglial cells, Schwann
cells, mature glial cells, ependymal cells, fibroblasts, and
endothelial cells [13,16,25]. It is likely that the ex vivo delivery of
VEGF promoted proliferation of these potentially proliferating
cells to a similar extent. Indeed, the mitogenic role of VEGF has
been demonstrated for very different kinds of neural cells. For
examples, application of VEGF increased the number of neuronal
cells in developing retina [26], and VEGF promoted proliferation
of astrocytes [27], Schwann cells [8], and neural stem or
progenitor cells [17]. In contrast to our present results, a previous
study reported that a single injection of VEGF immediately after
injury did not increase the number of BrdU+ cells [9]. The
discrepancy might be explained by more effective and stable
expression of VEGF by the ex vivo approach taken in this study.
Transplantation of F3.VEGF cells markedly increased the
extent of proliferation of NG2+ glial progenitor cells. NG2 and
PDGFa are coexpressed in O2A glial progenitor cells [28], and
there is evidence that NG2+ cells differentiate into mature
oligodendrocytes in vitro [29]. NG2 positive cells increase the
extent of proliferation after SCI [13], and proliferating NG2
positive cells are thought to differentiate into mature oligoden-
drocytes replacing the ones that are lost secondary to injury [14].
We found that ex vivo delivery of VEGF increased the number of
early proliferating cells that differentiated into mature oligoden-
drocytes at 6 weeks after SCI. These results suggest that VEGF
expanded a pool of proliferating NG2 positive cells after SCI that
eventually differentiated into mature oligodendrocytes. Notably,
the number of newly born astrocytes at 6 weeks after SCI was not
affected by F3.VEGF grafts. NG2+ cells could generate at least a
portion of GFAP+ astrocytes composing the glial scar [30]. Our
data suggest that the increase in proliferating NG2+ cells by
F3.VEGF grafts did not contribute to the generation of new
astrocytes in the glial scar. It is possible that proliferating NG2+
cells which are destined to take the astrocytic fate did not respond
to VEGF. Alternatively, the effects of VEGF on genesis of new
astrocytes might be antagonized by transplanted stem or
Figure 4. Long term fate of early proliferating glial progenitor cells. (A–B) Confocal images of BrdU incorporated cells colocalized with
mature oligodendrocyte marker CC1 (A) and astrocyte marker GFAP (B). Scale bars; 10 um. (C–D) The number of CC1+/BrdU+ (C) and GFAP+/BrdU+
(D) cells per 1 mm3 of spinal cord tissue was stereologically counted and compared between the three groups at 6 weeks after injury. * p,0.05 by
one-way ANOVA followed by Tukey’s posthoc analysis. N = 5 for each group.
doi:10.1371/journal.pone.0004987.g004
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progenitor cells as cellular vehicles that were shown to suppress
activation of astrocytic scars [31,32]. We did not find evidence that
new neurons were generated by any of the experimental
intervention. The molecular environment of the spinal cord is
predominantly gliogenic, but not conducive for the generation of
new neurons [33,34]. We assumed that VEGF provided by
F3.VEGF grafts could not overcome the limitation imposed by the
molecular niches in the spinal cord.
Increases in the number of proliferating NG2+ glial progenitor
cells and newly born oligodendrocytes can have important
implications in the recovery of neurological function after SCI.
Demyelinating lesions in the white matter are at least partially
responsible for functional deficits after SCI [35,36]. It has been
demonstrated that newly generated oligodendrocytes are capable
of remyelinating axons [16]. Therefore, it is conceivable that the
expanded pool of proliferating glial progenitor cells by F3.VEGF
could induce remyelination and lead to functional recovery. We
showed that F3.VEGF grafts markedly enhanced tissue sparing.
NG2 glial progenitor cells stimulated by VEGF might differentiate
into myelinating oligodendrocytes and enhance remyelination,
eventually leading to the increase in the volume of myelinated
white matter. It is also possible that neuroprotective effects and/or
angiogenic activity of VEGF played a more major role in
enhanced tissue sparing. A single injection of VEGF immediately
after SCI increased the density of blood vessels and decreased
apoptosis of neural cells [9]. Moreover, VEGF also prevented
retraction and promoted regeneration of the corticospinal axons
after spinal cord transection [37]. Therefore, enhanced tissue
sparing and the resulting improvement of locomotor function by
F3.VEGF could be ascribed to a combination of the multifaceted
trophic effects of VEGF on glial progenitor cells, endothelial cells,
neural cells, and injured axons.
In summary, we showed a successful delivery of VEGF to the
injured spinal cord tissue by genetically modified human NSCs as
cellular vehicles. VEGF overexpressing NSC graft exerted a
previously unreported effect of VEGF on glial progenitor cells
following SCI: transplantation of F3.VEGF increased the
proliferation of NG2+ glial progenitor cells and the number of
newly born oligodendrocytes. Therefore, VEGF can be therapeu-
tically utilized to repair white matter pathology in SCI. VEGF also
improved angiogenesis and tissue sparing, indicating multifaceted
actions for repair of injured spinal cord. The strategy of human
NSC-based VEGF delivery may have potential to be clinically
translated for the victims of SCI.
Figure 5. Promotion of angiogenesis by transplantation of F3.VEGF. (A–F) Representative images of spinal cord sections (6 weeks after
injury) stained with blood vessel marker vWF from PBS (A, D), F3 (B, E), and F3.VEGF (C, F) groups. Figures in the lower panel (D, E, F) are high power
images of the boxed regions in (A, B, C), respectively. Scale bars in the upper panel; 200 um. Scale bars in the lower panel; 50 um. (G) The fraction of
areas occupied by vWF immunoreactive vessels was compared between the three groups at the epicenter (designated as E) and 1.8 mm rostral and
caudal (designated as R and C, respectively). ** p,0.01, *** p,0.001 by one-way ANOVA followed by Tukey’s posthoc analysis. White, hatched, and
black bars represent PBS (N= 5), F3 (N= 5), and F3.VEGF (N= 5) groups, respectively.
doi:10.1371/journal.pone.0004987.g005
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Materials and Methods
Preparation of VEGF overexpressing human NSCs
Telencephalon tissue from a 15 weeks gestational human fetal
brain was utilized to generate primary cell culture from which
immortalized cell lines of human NSCs (F3 line) were generated
using a retroviral vector encoding v-myc oncogene. The permission
to use the fetal tissues was granted by the Clinical Research
Screening Committee involving Human Subjects of the University
of British Columbia, and the fetal tissues were obtained from the
Anatomical Pathology Department of Vancouver General Hospital.
PG13 mouse packaging cell line was transfected with plasmid
pLPCX-VEGF vector containing the full length human VEGF
cDNA, using Lipofectamine 2000 (Invitrogen, Carlsbed, CA), and
stable PG13 cell line was selected using 10 ug/ml puromycin for 3
days. Replication incompetent retroviral vector which was collected
from PG13.VEGF cells was used for transfection of F3 human
NSCs. Puromycin-resistant VEGF clones were screened and
isolated, and one of the clones (F3.VEGF line) was expanded and
used for the transplantation [38].
Animals and surgical procedures
Adult Sprague–Dawley female rats, weighing 200–250 gm,
were used in this study. Animal handling and surgical protocols
followed the regulations set by the Ajou University Institutional
Animal Care and Use Committee. After anesthetization with
chloral hydrate (400 mg/kg, i.p.), animals received a dorsal
laminectomy at the ninth thoracic vertebral level (T9) to expose
the spinal cord, and then were subjected to mechanical impact
with 180 kdyn force using the Infinite Horizon impactor (Precision
Systems and Instrumentation, Lexington, KY). Seven days after
injury, rats were randomly classified into three groups, and each
group received injections of PBS, F3, and F3.VEGF cells,
respectively. A total of 26105 cells, divided in two dosages, were
transplanted into injured spinal cord. Each injections was made at
2 mm rostral and 2 mm caudal from the lesion epicenter,
respectively, at a depth of 1.2 mm. At each site, 2 ul of cell
suspension containing 105 NSCs or vehicle was injected through a
glass micropipette with a tip diameter of less than 60 um at a rate
of 0.4 ul/min. All animals received daily intraperitoneal cyclo-
sporine (Sandimmun; Novartis, Bern, Switzerland) at a dosage of
10 mg/kg beginning from one day prior to transplantation to
three weeks after transplantation. After that, cyclosporine was
administered through drinking water (50 mg/ml) until sacrifice.
Bromodeoxyuridine (BrdU) injection
Cellular proliferation was examined using BrdU (Sigma, St.
Louis, MO). To study the extent of cellular proliferation within 7
days after transplantation, animals were intraperitoneally injected
Figure 6. Sparing of spinal cord tissue at 6 weeks after injury.
(A–I) Representative images of erichrome stained sections at the
1.8 mm rostral to the epicenter (A, D, G), epicenter (B, E, H), and 1.8 mm
caudal to the epicenter (C, F, I). (A–C) PBS, (D–F) F3, and (G–I) F3.VEGF
groups. Scale bar; 500 um. (J–L) The volumes of spared spinal cord
tissue (J), white matter (K), and lesion cavities (L) were calculated by
Cavelieri’s method and compared between the three groups. ** p,0.01,
followed by Tukey’s posthoc analysis. N = 8 for each group.
doi:10.1371/journal.pone.0004987.g006
Figure 7. Locomotor recovery assessed by Basso, Beattie, and
Bresnahan (BBB) test. Hind limbs locomotor function was scored as
from 0 to 21 (flaccid paralysis to normal gait). Rats with transplantation
of F3.VEGF showed significantly improved locomotor behavior up to 6
weeks after SCI. *** p,0.001 compared to PBS group, # p,0.05, ###
p,0.001 compared to F3 group, by one-way ANOVA followed by
Tukey’s posthoc analysis. N = 8 for each group.
doi:10.1371/journal.pone.0004987.g007
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with BrdU (50 mg/kg) for three consecutive days (4th, 5th, and
6th day), and then sacrificed the day after the last injection. To
examine phenotypic fate of early proliferating cells, animals were
injected with BrdU and were allowed to survive until the 35th day
after transplantation, and then were sacrificed for histological
analysis.
Western blot analysis and ELISA
Spinal cord tissues spanning65 mm from the epicenter were
dissected and homogenized in ice-cold lysis buffer containing the
followings: 20 mM Tris-HCl (pH 7.5), 1 mM EDTA, 5 mM
MgCl2, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluo-
ride, and protease inhibitor cocktail (Pierce, Rockford, IL). The
tissue homogenate was centrifuged at 4uC and 14,000 rpm for
20 min, and protein concentration of the supernatant was
measured using Bradford assay. Equal amounts of proteins were
resolved by PAGE and transferred to a PVDF membrane
(Millipore, Bedford, MA). The membrane was blocked in Tris
buffered saline (TBS) containing 2.0% BSA and probed with the
rabbit anti-flk-1 (1:2000; Thermo Scientific, Fremont, CA) and
rabbit anti-phospho-flk-1 (1:2000; Millipore Corporation, Bill-
erica, MA). After washing, the membranes were incubated for 1 hr
at room temperature with secondary antibodies (1:2000; Amer-
sham Biosciences, Arlington Heights, IL). Finally, the blots were
developed with enhanced chemiluminescence detection reagents
(Amersham Biosciences, Arlington Heights, IL). The blots were
reprobed with antibodies against mouse anti-b actin (1:5000;
Abcam, Cambridge, UK). Concentration of VEGF protein in
injured spinal cord tissue was measured using ELISA (R&D
systems, Minneapolis, MN) following an instruction manual
provided by the manufacturer.
Tissue processing and immunohistochemistry
Animals were deeply anesthetized with chloral hydrate and
perfused intracardially with PBS, followed by 4% paraformalde-
hyde in 0.1 M phosphate buffer, pH 7.4. Spinal cords were
removed and post-fixed in 4% paraformaldehyde for 2 hrs,
followed by immersion into a graded series of sucrose solution.
Cryosections of spinal cord were made transversely (section
thickness 20 mm) in a 1:10 series, and mounted onto SuperFrost
Plus slides (Fisher Scientific, Pittsburgh, PA). For BrdU immuno-
histochemistry, transverse spinal cord sections were treated with
10% hydrogen peroxide to quench endogenous peroxidase
activity, followed by incubation in 1 N HCl at 37uC for 30 min.
After thorough rinsing and blocking, tissue sections were incubated
with rat polyclonal anti-BrdU (1:500; Serotec, Oxford, UK) at
37uC for 1 hour in a humid chamber. Tissue sections were rinsed
and incubated with biotinylated horse anti-rat IgG secondary
antibody, and the antigen-antibody reaction was visualized by
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA)
with diaminobenzidine (DAB) substrate (Sigma-Aldrich, St. Louis,
MO). For double-labeling with anti-BrdU and various cellular
markers, transverse spinal cord sections were processed for BrdU
staining as above and then extensively rinsed in PBS-T. Sections
were blocked with the Avidin/Biotin blocking Kit (Vector
Laboratories, Burlingame, CA) and incubated overnight with the
second primary antibodies. After incubation with appropriate
biotinylated secondary antibodies, sections were further processed
using Vectastain Elite ABC kit with Vector SG peroxidase
substrate kit (Vector Laboratories, Burlingame, CA). Development
of antigen-antibody reactions with DAB substrate resulted in
brown colored precipitates, whereas SG substrate yields bluish
color, thus making it possible to identify two different cellular
markers in the same section. For immunofluorescence staining,
sections were incubated overnight with primary antibodies at 4uC
or for 2 hrs at room temperature, followed by appropriate
secondary antibodies tagged with Alexa Fluor 488 or Alexa Fluor
594 (Molecular Probes, Eugene, OR) for 45 min at room
temperature. We used polyclonal NG2 antibody (1:2000; Milli-
pore, Bedford, MA) as a marker for oligodendrocyte progenitors,
monoclonal CC1 antibody (1:100; Calbiochem, La Jolla, CA)
which recognizes adenomatous polyposis coli protein in cell bodies
of mature oligodendrocyte without labeling of oligodendrocytic
processes [39,40], and polyclonal GFAP antibody (1:500; Dako,
Carpinteria, CA) for mature astrocytes. Primary antibodies were
anti-BrdU, anti-GFAP, anti-CC1, monoclonal anti-human specific
mitochondria (1:500; Chemicon, Temecula, CA), anti-NeuN
(1:500; Chemicon, Temecula, CA), anti-MAP2 (1:500; Chemicon,
Temecula, CA), and polyclonal anti-von Willebrand Factor (vWF)
(1:250, Chemicon, Temecula, CA) which recognizes endothelial
cells that produce vWF proteins.
Stereological cell counts
The number of cells of interest was quantified using the
unbiased stereological estimation, based on the optical fractionator
method [41]. The Computer-Assisted Stereological Toolbox
system, version 2.1.4 (Olympus, Ballerup, Denmark) equipped
with an Olympus BX51 microscope, a motorized microscope stage
(Prior Scientific, Rockland, MA) run by an IBM-compatible
computer, and a microcastor (ND 281B, Heidenhain, Traunreut,
Germany) connected to the stage and feeding the computer with
the distance information in the z-axis was used. Using the injury
epicenter as a point of reference, every third section extending
rostral and caudal to the epicenter (sections spaced 200 um apart)
was sampled so that measurements spanned a total of 6 mm (11
sections per animal, including the epicenter). The injured spinal
cord was delineated at a 1.256 objective and generated counting
grid of 3006300 um. An unbiased counting frame of known area
superimposed on the image was placed randomly on the first
counting area and systemically moved through all counting areas
until the entire delineated area was sampled. Actual counting was
performed using a 1006 oil objective. The total number of cells
was divided by spared tissue volume measured as described below
to obtain the number of cells per 1 mm3 of spared tissue. Since the
volume of spared spinal cord tissue was different between the
groups, all the comparisons of the cell numbers between different
groups were based on the density (i.e. the number of cells per
1 mm3 of spared spinal cord tissue) rather than absolute number.
The number of cells at different regions from the epicenter was
counted at the corresponding sections, and then was divided by
the subvolume of the corresponding regions.
Quantification of spinal cord tissue volume and
microvessel density
To quantify the amount of white matter spared after SCI,
sections surrounding the injury epicenter were stained with myelin
specific eriochrome-cyanine RC [42]. Digitized photographs of
the stained sections were taken using Olympus DP71 microscopy
camera (Olympus, Ballerup, Denmark). The volume of spared
spinal cord tissue was analyzed by the method of Cavalieri’s
principle [43]. The total cross-sectional areas of the spinal cord
and the areas of cavity were stereologically measured using the
Castor system. The areas of spared tissue were calculated by
subtracting the cavity areas from the total cross sectional areas.
The individual subvolumes of spared spinal cord tissue were
obtained by multiplying the cross-sectional areas of spared tissue
by the distance between sections, and the subvolumes were added
to obtain the total volume of spared spinal cord tissue. Endothelial
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cell marker vWF stained sections were scanned at low power to
determine the areas of highest vascular density. Within this region,
3 rectangular fields of interest were randomly selected at 206
objective lens. The areas occupied by vWF positive microvessels
were measured using the publically available image J software
(http://rsb.info.nih.gov/ij/index.html), and were divided by the
total areas of the corresponding fields to obtain the density of
microvessels in the injured spinal cord tissue
Analysis of locomotor behavior
The recovery of gross overground locomotion was evaluated
within 24 hrs after an initial injury, within 24 hrs after
transplantation or vehicle injection and once a week thereafter
using the Basso, Beattie, and Bresnahan (BBB) open field
locomotor test [44]. After transplantation, animals were assigned
a randomized code to ensure blind evaluation of locomotor
performance (PBS N=8, F3 N=8, F3.VEGF N=8). BBB score
was determined 7 times; within 24 hrs after an initial injury, within
24 hrs after transplantation or vehicle injection, and then once a
week until 6 weeks after injury. Its scale ranges from 0 to 21, with 0
given to animals with no observable hindlimb movement and 21
given to animals with completely normal open field locomotor
function.
Statistical analysis
All statistical analyses were performed using the PRISM 4.0
statistical software package (Graphpad, Inc., San Diego, CA).
Differences among experimental groups were evaluated by a one-
way ANOVA followed by a Tukey’s posthoc analysis. Repeated
measures two-way ANOVA was used to compare matched data at
multiple time points. Significance for all statistical analysis was set
at p,0.05. Error bars in all graphs depict standard deviation (SD)
of measured variables.
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